Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Jefferies Group raised their Q3 2017 EPS estimates for Ionis Pharmaceuticals in a report issued on Tuesday. Jefferies Group analyst E. Yang now expects that the company will post earnings per share of $0.07 for the quarter, up from their prior estimate of ($0.31). Jefferies Group has a “Underperform” rating and a $18.00 price target on the stock. Jefferies Group also issued estimates for Ionis Pharmaceuticals’ Q4 2017 earnings at ($0.17) EPS, FY2017 earnings at ($0.16) EPS, FY2018 earnings at ($1.11) EPS, FY2019 earnings at ($0.90) EPS, FY2020 earnings at ($0.48) EPS and FY2021 earnings at ($0.32) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. The company had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 17.34%. The business’s revenue was up 170.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.47) EPS.

TRADEMARK VIOLATION WARNING: “Q3 2017 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Boosted by Jefferies Group” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/q3-2017-eps-estimates-for-ionis-pharmaceuticals-inc-nasdaqions-boosted-by-jefferies-group/1471886.html.

A number of other equities analysts have also recently issued reports on IONS. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 target price on the stock in a report on Monday, July 31st. Sanford C. Bernstein assumed coverage on shares of Ionis Pharmaceuticals in a report on Thursday, July 27th. They issued a “market perform” rating and a $57.00 target price on the stock. Stifel Nicolaus raised their target price on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, July 26th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $62.00 price target (up previously from $59.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, July 12th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $47.13.

Ionis Pharmaceuticals (IONS) opened at 45.56 on Friday. Ionis Pharmaceuticals has a 12 month low of $24.58 and a 12 month high of $60.01. The firm has a market cap of $5.65 billion, a PE ratio of 219.04 and a beta of 3.14. The company has a 50-day moving average price of $52.74 and a 200 day moving average price of $46.90.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Parallel Advisors LLC raised its position in Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after buying an additional 800 shares in the last quarter. Hanseatic Management Services Inc. bought a new position in Ionis Pharmaceuticals during the first quarter worth approximately $138,000. Westpac Banking Corp bought a new position in Ionis Pharmaceuticals during the first quarter worth approximately $171,000. Cambridge Investment Research Advisors Inc. bought a new position in Ionis Pharmaceuticals during the second quarter worth approximately $222,000. Finally, Cheyne Capital Management UK LLP bought a new position in Ionis Pharmaceuticals during the second quarter worth approximately $249,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

In related news, Chairman Stanley T. Crooke sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $55.35, for a total transaction of $608,850.00. Following the transaction, the chairman now owns 48,014 shares in the company, valued at $2,657,574.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP C Frank Bennett sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $59.29, for a total transaction of $592,900.00. Following the transaction, the senior vice president now owns 25,041 shares in the company, valued at approximately $1,484,680.89. The disclosure for this sale can be found here. Insiders have sold 54,379 shares of company stock worth $2,946,052 in the last quarter. Company insiders own 1.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.